Many eyes on human clinical trials that have begun in Quebec on a potential vaccine for COVID-19
“We are thrilled to see our COVID-19 vaccine candidate enter the Phase 1 trial, and we look forward to obtaining safety and immunogenicity results in October,” said Nathalie Landry, Executive Vice-President, Scientific and Medical Affairs at Medicago. “Our progress continues to demonstrate the value of Medicago’s unique plant-based vaccine technology.”
Officials at the company caution that even if proven viable it won’t bring the virus to a screeching halt.
It won’t be perfect they say, but they’re confident something will come of it.
“Creating a sufficient supply of COVID-19 vaccines within the next year is a challenge which will require multiple approaches, with different technologies,” said Dr. Bruce Clark, President and CEO of Medicago.
They admit it will probably take years to come up with the ‘right approach’.
A potential vaccine in the U.S. is also heading into the final phase of testing.
The experimental vaccine, developed by the National Institutes of Health and Moderna Inc., will start its most important step around July 27: A 30,000-person study to prove if the shots really are strong enough to protect against the virus.
A vaccine is considered the key to lifting all restrictions related to the pandemic.